Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.
The effect of recombinant human interleukin-2 (rIL-2) on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice was examined. rIL-2 was administered subcutaneously once a day for 7 or 14 days, starting 2 weeks after the mice were infected. Administration of 2 or 20 micrograms of rIL-2 per mouse daily for 7 days reduced bacterial counts in the lungs dose dependently. At a dose of 0.2 microgram per day, proliferation of bacteria in the lungs was suppressed after 14 days of administration. Agglutinin titers in serum were not affected by rIL-2 treatment. Monocyte and lymphocyte counts in peripheral blood were increased by administration of 20 micrograms of rIL-2 daily for 14 days but not by treatment for 7 days. In addition, clearance of bacteria from the lungs after aerosol exposure was enhanced by treatment for 7 days before infection. Thus, rIL-2 acted therapeutically or prophylactically in the presence or absence, respectively, of a specific antigen. These effects were not abolished by anti-asialo GM1 antibody. This suggests that activation of natural killer cells does not play a critical role in the therapeutic and prophylactic effects of rIL-2.
Iizawa
Y
Y
Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Nishi
T
T
Kondo
M
M
Tsuchiya
K
K
Imada
A
A
D000336:Aerosols; D000372:Agglutination Tests; D000818:Animals; D000906:Antibodies / Q000502:physiology; D002908:Chronic Disease; D005260:Female; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000276:immunology; D007376:Interleukin-2 / Q000494:pharmacology*; D007700:Kinetics; D007710:Klebsiella Infections / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000254:growth & development; D007958:Leukocyte Count; D008171:Lung Diseases / Q000382:microbiology; D051379:Mice; D008808:Mice, Inbred CBA; D011994:Recombinant Proteins / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*
D000336:Aerosols; D000906:Antibodies; D006028:Glycosphingolipids; D007376:Interleukin-2; D011994:Recombinant Proteins; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside